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Introduction
COPD has been increasingly recognised as a
chronic inflammatory disease characterised by
sputum neutrophilia and, in some cases,
eosinophilia [1]. Use of induced sputum cell
counts has been largely proposed as a non-inva-
sive technique to investigate airway inflammation
in asthma and COPD [2, 3]. The technique of spu-
tum induction allows the study of COPD patients
during exacerbation as it is safe and well tolerated
[4]. Neutrophilic inflammation is further in-
creased during exacerbation [5]. Moreover, the
presence of eosinophilic inflammation can be de-
tected during exacerbation in subjects with
COPD. Sputum eosinophilia identifies a subgroup
of patients who particularly respond to corticos-
teroid treatment [6].
Case Report
A 68 year old man attended for routine review
of his COPD complaining that he had recently been
more breathless. His record reported a concomitant
history of hypertension and hypercholesterolemia.
He had a full-time commercial job with his wife.
The man smoked ten cigarettes per day; he had a 25
pack-year history of smoking. He tried to quit
smoking with the aid of nicotine patch, but his pe-
riods of abstinence had been short. He had two
courses of antibiotics and oral steroids for exacer-
bations in the last 12 months. He produced copious
sputum and chronic cough in the mornings. Current
medications includes a salmeterol/fluticasone com-
bination inhaler, a tiotropium inhaler, ramipril,
atorvastatin. On physical examination the lung
sounded hyperinflated and had decreased breath
sounds with some bilateral wheezes. The heart
sounds were normal. A chest x-ray showed hyper-
inflation. Spirometry result: FVC 3.36 L (89% of
predicted value); FEV11.38 L (47% pred.). Oxygen
saturation was 96%. Induced sputum cell count at
baseline: neutrophils 78%, eosinophils 3%.
Three months later the man attended to the
out-patient office for urgent visit for COPD exac-
erbation (increase cough, increase purulent yel-
low/green sputum production, increased breath-
less). There were some crackles without wheezes
on thoracic examination. Spirometry result: FVC
3.18 L (84% pred.); FEV11.20 L (41% pred.).
Oxygen saturation was 92%. Induced sputum cell
count: neutrophils 95%, eosinophils 1% (fig. 1).
The man was treated with a course of antibiotics
(Levofloxacin 500 mg/die - seven days) without
oral steroids and continued his therapy with in-
haled bronchodilators and steroids. Symptoms and
the sputum purulence were reduced after 10 days;
oxygen saturation was 95%.
Seven months later the man attended the ER
for serious breathless and wheezing. The entity
and the colour of the sputum did not significantly
change. On physical examination there were an in-
creased sounds mainly wheezes. Spirometry was
not done and oxygen saturation was 90%. The pa-
tient was treated with inhaled salbutamol + iprat-
ropium and theophylline + corticosteroids i.v. and
a prescription of antibiotics (Levofloxacin 500
mg/day). The day after he attended our lab and
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ABSTRACT: Induced sputum in the management of COPD:
clinical implications. A. Zanini, S. Della Patrona, A.L.
Facchini, A. Spanevello.
Sputum induction can be used as a non-invasive tech-
nique to investigate airway inflammation in asthma and
COPD. We reported the case of a 68 year old man with
COPD, stage III GOLD, that underwent sputum induction
during two exacerbation episodes. The first cell count showed
a typical sputum neutrophilia, whereas the second showed
sputum eosinophilia. On the basis of sputum cellularity, we
decided to treat the first episode with a course of antibiotics
and the second exacerbation with a course of antibiotics and
oral steroids. The patient showed improvement in both cases,
obtaining clinical stabilisation. The induced sputum cell count
could be a useful technique in a clinical setting to evaluate the
cellular characteristics of airway inflammation during COPD
exacerbation and modulate the antinflammatory therapy.
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Discussion
While chronic asthma is characterised by in-
creased numbers of eosinophils in the sputum,
COPD is characterised by increased numbers of
neutrophils, although an increase in the numbers
of neutrophils may also found in asthmatic patients
[2, 3]. Many inflammatory mediators have been
analysed in the fluid-phase of induced sputum.
Several cytokines, chemokines, eicosanoids,
markers of oxidative stress show an increase in
COPD compared to asymptomatic smokers, with a
further increase during exacerbations. Moreover,
sputum fluid-phase in COPD shows an increase in
neutrophilic granulocyte proteins and others mole-
cules, that represent markers of neutrophil activa-
tion [5]. All these findings indicate that neu-
trophils are relevant in the pathogenesis of COPD,
and there is a negative correlation between neu-
trophil count and the decline of FEV1 [7].
We can use induced sputum to monitor inflam-
mation in COPD. Interestingly, sputum cells were
analysed on three sepa-
rate occasions at four-
weekly intervals [3].
Moderate, clinically
stable COPD was as-
sociated with stable in-
duced-sputum inflam-
matory markers, and
the quantification of
most cellular and solu-
ble components is suf-
ficiently reproducible
[3]. Serial monitoring
of inflammation in
COPD using surrogate
markers of induced
sputum is a suitable
tool for clinical rou-
tine, research purpos-
es, and clinical trials.
Additionally, spu-
tum induction can be
safely carried out in
patients with mild-to-
moderate COPD who
Fig. 1. - Induced sputum showing a high percentage of neutrophils 
(H & E Stain, 10X).
Fig. 2. - Induced sputum showing a high percentage of eosinophils 
(H & E Stain, 10X).
Fig. 3. - Schematic diagram of the case history reporting the clinical phases and the percentages of sputum cells.
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spirometry + induced sputum were performed.
Spirometry result: FVC 3.40 L (90% pred.);
FEV11.29 L (44% pred.). Oxygen saturation was
94%. Induced sputum cell count: neutrophils 74%,
eosinophils 11% (fig. 2). The main causes of sys-
temic eosinophilia – such as allergies (including al-
lergic rhinitis and nasal polyposis), parasitic infec-
tions, neoplasms and immune disorders  – were ex-
cluded. A course of oral steroids was started (Pred-
nisone 25 mg/ die for seven days, then 12.5 mg/die
for five days). Cough and wheezing were largely
reduced after five days of oral steroids treatment.
One month later a sputum induction was per-
formed: neutrophils 81%, eosinophils 3%. A
schematic diagram of the case history reporting the
clinical phases and the percentages of sputum cells
is reported in figure 3.
The induced sputum cell count could be a use-
ful technique in a clinical setting to evaluate the
cellular characteristics of airway inflammation
during COPD exacerbation and modulate the anti-
inflammatory therapy.
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experienced an exacerbation, and this occurs with
no greater risk than in stable patients with COPD.
This finding is very important, considering that
acute exacerbations play an important role on the
natural history of COPD. Bathoorn et al. per-
formed sputum induction in COPD patients, both
in the stable phase and during exacerbation [4]. In
this study, the median FEV1 for the stable phase
and exacerbation were 61% and 51% of predicted,
respectively, and the median decrease in FEV1
with sputum induction during an exacerbation was
0.27 l vs 0.28 l during the stable phase [4].
Although COPD is mainly a neutrophilic air-
way disease, a substantial part of patients fitting
the functional definition of COPD exhibit signifi-
cant sputum eosinophilia (>3%) [8]. There is in-
creasing evidence that the presence of sputum
eosinophilia predicts an objective response to oral
and inhaled corticosteroid treatment in COPD [6,
8-10]. Brightling et al. reported that the response
in term of lung function to a two-week course of
oral prednisolone increased as the baseline sputum
eosinophilia count increased, and was associated
with a marked treatment-induced fall in the spu-
tum eosinophil count, but no change in sputum
markers of neutrophilic inflammation [6]. More-
over, Siva et al. showed that a management ap-
proach over a 12-month period with the additional
aim of reducing the sputum eosinophil count <3%
using corticosteroids was associated with a 62%
reduction in severe exacerbation of COPD requir-
ing hospitalisation when compared to traditional
symptom-based management [9]. Based on these
reports, a measurement of sputum eosinophil
counts could be used to identify COPD patients
with corticosteroids responsive disease and to
guide treatment.
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